- Home
- HIVE vs CRMD Comparison
HIVE vs CRMD Comparison
Compare HIVE & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIVE | CRMD |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.2M | 626.0M |
| IPO Year | 2017 | 2009 |
Fundamental Metrics
Financial Performance| Metric | HIVE | CRMD |
|---|---|---|
| Price | $4.09 | $8.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $6.44 | ★ $14.83 |
| AVG Volume (30 Days) | ★ 23.9M | 1.3M |
| Earning Date | 02-17-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | $169.51 | $0.30 |
| Revenue Next Year | $39.45 | N/A |
| P/E Ratio | ★ N/A | $18.58 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $1.60 | $6.13 |
| 52 Week High | $7.84 | $17.43 |
Technical Indicators
Market Signals| Indicator | HIVE | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 73.65 | 56.38 |
| Support Level | $2.64 | $6.28 |
| Resistance Level | $4.33 | $8.74 |
| Average True Range (ATR) | 0.34 | 0.39 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 89.81 | 37.09 |
Price Performance
Historical ComparisonAbout HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.